Skip to content
Search

Latest Stories

Jaguar Land Rover May Axe Thousands Of UK Jobs

Tata Motors owned UK’s largest car producer, Jaguar Land Rover (JLR) is on its way to make an announcement to axe thousands of jobs as the auto giant faces significant fall in demand in China and a decline in diesel car sale in Europe, media reports said on Thursday (10).

The auto firm has prepared plans to reduce costs and raise cash flows by £2.5 billion. The plans include reducing employment costs and levels, Reuters reported citing a source who disclosed the plans on condition of anonymity.


There may be substantial job losses impacting managerial, sales, design, and other departments. However, the production-line staff will not be affected at this stage.

The firm produces a major proportion of its cars in Britain than any other major or medium sized car company. The automaker has also spent millions of pounds to prepare for Brexit, in the case of there are tariffs.

The automaker swung to a loss of £354 million during April to September period and had cut around 1000 roles in the UK in 2018. The firm had shut its Solihull plant for 14 days and announced a three-day week at its Castle Bromwich site.

JLR which has a staff strength of 40, 000 in the UK and had been adding new employees to its workforce at new plants in China and Slovakia in recent years.

Sales in China during July and September fell by 44 per cent, the biggest fall for the automaker.

Diesel accounts for 90 per cent of the firm's British sales and 45 per cent of global demand, the company said last year, as demand in the segment tumbles following new levies in the wake of the 2015 Volkswagen emissions cheating scandal.

Diesel accounts for 90 per cent of the automaker’s sales in Britain and 45 per cent of world demand, according to the company.

Akin other auto manufacturers, the JLR could see its three British car plans grind to a halt within 80 days if lawmakers reject a deal by British prime minister Theresa May next week, leading to tariffs and customs checks after a no-deal outcome.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less